Mechanisms for improved survival in heart failure

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Congestive heart failure (CHF) leads to death via progressive failure or sudden cardiac death, often due to ventricular arrhythmias.
• Myocardial metabolic factors and neuroendocrine activation are implicated in CHF progression and arrhythmias.
• Current antiarrhythmic agents have not convincingly reduced sudden death in CHF patients.

Purpose of the Study:

• To investigate the association between neuroendocrine activation and myocardial function deterioration in CHF.
• To evaluate the efficacy of angiotensin-converting enzyme (ACE) inhibitors in managing CHF mortality.

Main Methods:

• The CONSENSUS study assessed the impact of enalapril (an ACE inhibitor) on CHF mortality.
• Blood samples were analyzed for neuroendocrine markers (angiotensin II, aldosterone, noradrenaline, atrial natriuretic peptide) in relation to mortality.
• Patients were stratified based on baseline hormone levels and enalapril treatment.

Main Results:

• Enalapril treatment reduced overall one-year mortality by 31% in CHF patients.
• This mortality reduction was primarily observed in patients with progressive CHF (50% reduction), with no significant impact on sudden death.
• Elevated baseline levels of angiotensin II, aldosterone, noradrenaline, and atrial natriuretic peptide correlated with increased mortality in placebo-treated patients but not in enalapril-treated patients.

Conclusions:

• Neuroendocrine activation plays a significant role in the progressive deterioration of myocardial function in CHF.
• ACE inhibitors, such as enalapril, effectively reduce mortality in CHF, particularly by mitigating progressive failure.
• Targeting neuroendocrine pathways with ACE inhibitors offers a promising therapeutic strategy for managing CHF.